Spero Therapeutics Stock Rises Above 50-Day Moving Average

Shares of the biotech company climb after positive news, but analysts remain cautious on the stock's outlook.

Apr. 16, 2026 at 7:38am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of gears, levers, and metal components, representing the complex financial and technological infrastructure underlying the biotech industry.The intricate, high-stakes mechanics of the biotech industry are reflected in Spero Therapeutics' volatile stock price movements.Boston Today

Shares of Spero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on developing novel antibiotics, rose above their 50-day moving average on Wednesday. The stock traded as high as $2.80 before closing at $2.64, with trading volume of 694,473 shares.

Why it matters

Crossing above the 50-day moving average is often seen as a bullish technical signal, indicating the stock may be entering a period of positive momentum. However, Wall Street analysts remain divided on Spero's prospects, with one rating the stock a 'strong sell' and another upgrading it to 'strong buy'.

The details

Spero Therapeutics is developing an oral carbapenem antibiotic called tebipenem HBr to treat complicated urinary tract infections caused by resistant Gram-negative pathogens. The company recently reported quarterly results that included a surprise profit, sending the stock higher.

  • Spero Therapeutics shares crossed above the 50-day moving average of $2.42 on Wednesday, April 16, 2026.
  • The company reported Q1 2026 earnings on March 26, 2026.

The players

Spero Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat serious bacterial infections.

Wall Street Zen

An equity research firm that upgraded Spero Therapeutics to a 'strong-buy' rating.

Weiss Ratings

An equity research firm that maintained a 'sell (d-)' rating on Spero Therapeutics.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching to see if Spero Therapeutics can maintain its momentum and build on the recent positive news. The company's progress with its lead drug candidate, tebipenem HBr, will be a key focus going forward.

The takeaway

Spero Therapeutics' stock price movement highlights the volatility and uncertainty surrounding small-cap biotech companies developing novel antibiotic treatments. While the recent earnings surprise provided a boost, the mixed analyst views suggest the stock remains a high-risk, high-reward proposition for investors.